ABL Bio is seeking to transform itself from a licensing-focused biotech company into a globally competitive drug developer ...

Traders are watching for the 80th event, data lock and topline results, while some are also speculating about potential M&A.

Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong ...

Island Pharmaceutical’s experimental drug will be used to treat patients in Uganda, as the African nation grapples with the ...

The parent of bankESB and TruNorth Bank will end its 157-year history as a depositor-owned institution, in part to fund the ...

The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...

The deal values Crinetics at $85 per share in cash, representing a potential upside of about 100% from the stock’s closing ...

Under the licensing deal signed earlier this year, Aligos granted Xiamen Amoytop Biotech exclusive rights to develop and sell its experimental hepatitis B treatment drug, pevifoscorvir sodium, in ...

Japanese biotech drug aims to reverse tooth loss by regrowing teeth. Here's how TRG-035 works, where trials stand and when it ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

Preview this article 1 min A Madrid, Spain-based cancer diagnostic firm seeks to grow its footprint to 21,000-square-foot at ...

Swiss pharma heavyweight Novartis is cutting a very large check. The company has agreed to acquire London-headquartered ...